Nithya M. Baiju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nithya M. Baiju has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Nittin Henry
MVR Canc Ctr, Dept Transfus Med, Calicut, India
2 shared publicationsSusheela Jacob Innah
Jubilee Mission Med Coll & Res Inst, Dept Transfus Med, Trichur 680005, Kerala, India
2 shared publicationsAboobacker Mohamed Rafi
Jubilee Mission Med Coll & Res Inst, Dept Transfus Med, Trichur 680005, Kerala, India
1 shared publication- Aiswarya Venugopal
Department of Community Medicine, Jubilee Mission Medical College and Research Institute, Thrissur 680005, Kerala, India
1 shared publication - Akhila Kallempadam
Department of Community Medicine, Sree Narayana Institute of Medical Sciences, Ernakulam, Kerala, India
1 shared publication - Alex George
Jubilee Centre for Medical Research, Jubilee Mission Medical College and Research Institute, Thrissur, Kerala, India
1 shared publication
Latest Publications
- Open Access
Real-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India—An Ambi-Directional Cohort Study
Background: Vaccine effectiveness for first-generation coronavirus disease (COVID-19) vaccines among People Living with HIV (PLHIV) in India remains unexplored. This study entails the estimation of the real-world effectiveness of COVID-19 vaccines (AZD1222/Covishield, BBV152/Covaxin) among PLHIV and the identification of variants of SARS-CoV-2 among those infected with COVID-19. Methods: An ambi-directional cohort study was conducted among 925 PLHIV above 18 years of age in two districts of central Kerala, India, from February 2022 to March 2023. Selected PLHIV were recruited as Participant Liaison Officers (PLOs) for the follow-up on the study participants. At enrolment, basic details, baseline CD4 count, and a Nasopharyngeal (NP) swab for RT-PCR were collected. In the follow-up phase, NP swabs were collected from subjects with COVID-19 symptoms. Positive subjects had a CD4 count and genomic sequencing performed. Results: The mean age of the participants was 46.93 ± 11.00 years. The majority, 819 (93.6%), of participants had received at least one dose of any vaccine, while 56 (6.4%) were unvaccinated. A total of 649 (79.24%) participants were vaccinated with Covishield and 169 (20.63%) with Covaxin. In the vaccinated group, 158 (19.3%) reported COVID-19 infection. Vaccine Effectiveness (VE) for one dose of any vaccine was 43.2% (95% CI: 11.8–64.5), p = 0.015. The effectiveness of full vaccination with Covishied was 63.8% (95% CI: 39.3–79.2), p < 0.001, and Covaxin was 73.4% (95% CI: 44.3–87.3). VE was highest, at 60.7% (95% CI: 23.6–81.3), when the two doses of the vaccine were given at an interval of less than 6 weeks. Participants with a baseline CD4 count > 350 had greater protection from COVID-19, at 53.4% (95% CI: 19.6–75.3) p = 0.004. The incident cases were sub-variants of Omicron (BA.2, BA.2.38, BA.2.10). Conclusions: Full vaccination with Covishield and Covaxin was effective against COVID-19 infection among PLHIV on treatment; albeit, that of Covaxin was higher. A gap of 4 to 6 weeks between the two doses of COVID-19 vaccine was found to have higher VE among PLHIV.
Open AccessReal-World Effectiveness of COVID-19 Vaccine and Identification of SARS-CoV-2 Variants among People Living with HIV on Highly Active Antiretroviral Therapy in Central Kerala of India—An Ambi-Directional Cohort Study
Background: Vaccine effectiveness for first-generation coronavirus disease (COVID-19) vaccines among People Living with HIV (PLHIV) in India remains unexplored. This study entails the estimation of the real-world effectiveness of COVID-19 vaccines (AZD1222/Covishield, BBV152/Covaxin) among PLHIV and the identification of variants of SARS-CoV-2 among those infected with COVID-19. Methods: An ambi-directional cohort study was conducted among 925 PLHIV above 18 years of age in two districts of central Kerala, India, from February 2022 to March 2023. Selected PLHIV were recruited as Participant Liaison Officers (PLOs) for the follow-up on the study participants. At enrolment, basic details, baseline CD4 count, and a Nasopharyngeal (NP) swab for RT-PCR were collected. In the follow-up phase, NP swabs were collected from subjects with COVID-19 symptoms. Positive subjects had a CD4 count and genomic sequencing performed. Results: The mean age of the participants was 46.93 ± 11.00 years. The majority, 819 (93.6%), of participants had received at least one dose of any vaccine, while 56 (6.4%) were unvaccinated. A total of 649 (79.24%) participants were vaccinated with Covishield and 169 (20.63%) with Covaxin. In the vaccinated group, 158 (19.3%) reported COVID-19 infection. Vaccine Effectiveness (VE) for one dose of any vaccine was 43.2% (95% CI: 11.8–64.5), p = 0.015. The effectiveness of full vaccination with Covishied was 63.8% (95% CI: 39.3–79.2), p < 0.001, and Covaxin was 73.4% (95% CI: 44.3–87.3). VE was highest, at 60.7% (95% CI: 23.6–81.3), when the two doses of the vaccine were given at an interval of less than 6 weeks. Participants with a baseline CD4 count > 350 had greater protection from COVID-19, at 53.4% (95% CI: 19.6–75.3) p = 0.004. The incident cases were sub-variants of Omicron (BA.2, BA.2.38, BA.2.10). Conclusions: Full vaccination with Covishield and Covaxin was effective against COVID-19 infection among PLHIV on treatment; albeit, that of Covaxin was higher. A gap of 4 to 6 weeks between the two doses of COVID-19 vaccine was found to have higher VE among PLHIV.
- Open Access
- 18 April 2023
- Published by Penerbit Universiti Sains Malaysia in Malaysian Journal of Medical Sciences
- Vol. 30 (2) , 124-130
Is It Time to Switch from Conventional Coombs Crossmatching to the Type and Screen Protocol?
Background: ABO grouping, Rh typing and crossmatching are routinely done as part of pre-transfusion testing. The Type and Screen (T&S) protocol has been used in developed countries to ensure the survival of transfused red cells. In this study, we compared the safety, costs and turnaround times (TATs) of the T&S protocol and the conventional pre-transfusion testing protocol for patients who had been scheduled for elective obstetrical or gynaecological procedures.Methods: This observational study was conducted in three phases at the Department of Transfusion Medicine, Jubilee Mission Medical College and Research Institute, Kerala, India and involved 1,800 patients from the Department of Obstetrics and Gynaecology, Jubilee Mission Medical College & Research Institute, Kerala, India over the course of 2 years. Phase I involved the traditional pre-transfusion testing and crossmatching of 150 patients. Phase II involved the use of the T&S protocol on 150 patients. Phase III involved the use of both the traditional and T&S protocols on 1,500 patients without considering the results of each protocol. The safety, costs and TATs of both protocols were compared.Results: In this study, the T&S protocol provided a safety 100% level when compared to the traditional protocol. The T&S protocol detected unexpected antibodies in 0.4% of cases, which would have gone unnoticed otherwise, demonstrating its usefulness. There was no significant difference in cost between the traditional crossmatching and T&S protocols. We discovered that using only the T&S protocol can save technologists 30% of their time.Conclusion: Implementing the T&S protocol as a pre-transfusion testing procedure can help improve hospital transfusion practices by supplying blood quickly and safely. Coombs crossmatching remains more of a tradition than a necessity.
- 18 April 2023
- Published by Penerbit Universiti Sains Malaysia in Malaysian Journal of Medical Sciences
- Vol. 30 (2) , 124-130
Open AccessIs It Time to Switch from Conventional Coombs Crossmatching to the Type and Screen Protocol?
Background: ABO grouping, Rh typing and crossmatching are routinely done as part of pre-transfusion testing. The Type and Screen (T&S) protocol has been used in developed countries to ensure the survival of transfused red cells. In this study, we compared the safety, costs and turnaround times (TATs) of the T&S protocol and the conventional pre-transfusion testing protocol for patients who had been scheduled for elective obstetrical or gynaecological procedures.Methods: This observational study was conducted in three phases at the Department of Transfusion Medicine, Jubilee Mission Medical College and Research Institute, Kerala, India and involved 1,800 patients from the Department of Obstetrics and Gynaecology, Jubilee Mission Medical College & Research Institute, Kerala, India over the course of 2 years. Phase I involved the traditional pre-transfusion testing and crossmatching of 150 patients. Phase II involved the use of the T&S protocol on 150 patients. Phase III involved the use of both the traditional and T&S protocols on 1,500 patients without considering the results of each protocol. The safety, costs and TATs of both protocols were compared.Results: In this study, the T&S protocol provided a safety 100% level when compared to the traditional protocol. The T&S protocol detected unexpected antibodies in 0.4% of cases, which would have gone unnoticed otherwise, demonstrating its usefulness. There was no significant difference in cost between the traditional crossmatching and T&S protocols. We discovered that using only the T&S protocol can save technologists 30% of their time.Conclusion: Implementing the T&S protocol as a pre-transfusion testing procedure can help improve hospital transfusion practices by supplying blood quickly and safely. Coombs crossmatching remains more of a tradition than a necessity.
- Open Access
- 15 July 2016
- Published by Journal of Case Reports in Journal of Case Reports
- Vol. 6 (3) , 317-320
Management of Coagulopathy in Acute Fatty Liver of Pregnancy
A 31-year-old primigravida at 33 weeks of gestation with precious twin pregnancy was referred from a peripheral hospital with jaundice, malaise and hypoglycaemia. A clinical diagnosis of acute fatty liver of pregnancy progressing to coagulopathy was made. Emergency Caesarean section was performed and obstetric hysterectomy had to be done to control the bleeding. Timely management by obstetrician, anaesthetist and prompt component therapy by transfusion medicine specialist resulted in a successful outcome. The most advocated ratio of transfusing blood products in massive transfusion is 1:1:1 (packed red cells: fresh frozen plasma: platelets).
- 15 July 2016
- Published by Journal of Case Reports in Journal of Case Reports
- Vol. 6 (3) , 317-320
Open AccessManagement of Coagulopathy in Acute Fatty Liver of Pregnancy
A 31-year-old primigravida at 33 weeks of gestation with precious twin pregnancy was referred from a peripheral hospital with jaundice, malaise and hypoglycaemia. A clinical diagnosis of acute fatty liver of pregnancy progressing to coagulopathy was made. Emergency Caesarean section was performed and obstetric hysterectomy had to be done to control the bleeding. Timely management by obstetrician, anaesthetist and prompt component therapy by transfusion medicine specialist resulted in a successful outcome. The most advocated ratio of transfusing blood products in massive transfusion is 1:1:1 (packed red cells: fresh frozen plasma: platelets).